EARNEST Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

EARNEST Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,400	Closed	-$91K	–	1175
2018 Q3	$91K	Hold	4,400	–	–	﹤0.01%	270
2018 Q2	$67K	Sell	4,400 -31	-0.7%	-$553	﹤0.01%	282
2018 Q1	$100K	Hold	4,431	–	–	﹤0.01%	266
2017 Q4	$133K	Buy	+4,431	New	+$142K	﹤0.01%	244
2017 Q1	–	Sell	-4,431	Closed	-$128K	–	233
2016 Q4	$128K	Buy	4,431 +31	+0.7%	+$820	﹤0.01%	232
2016 Q3	$140K	Hold	4,400	–	–	﹤0.01%	221
2016 Q2	$143K	Hold	4,400	–	–	﹤0.01%	226
2016 Q1	$123K	Hold	4,400	–	–	﹤0.01%	234
2015 Q4	$157K	Hold	4,400	–	–	﹤0.01%	225
2015 Q3	$146K	Hold	4,400	–	–	﹤0.01%	224
2015 Q2	$184K	Hold	4,400	–	–	﹤0.01%	217
2015 Q1	$143K	Hold	4,400	–	–	﹤0.01%	220
2014 Q4	$140K	Hold	4,400	–	–	﹤0.01%	230
2014 Q3	$109K	Hold	4,400	–	–	﹤0.01%	222
2014 Q2	$99K	Hold	4,400	–	–	﹤0.01%	232
2014 Q1	$107K	Sell	4,400 -1,900	-30%	-$48.1K	﹤0.01%	229
2013 Q4	$157K	Buy	+6,300	New	+$149K	﹤0.01%	232

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

EARNEST Partners's ACAD Position: Q4 2018 in Review

EARNEST Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 4,400 shares — an estimated $91K sold.

EARNEST Partners first reported a position in ACAD in Q4 2013 and held it in 17 quarters. The position peaked at $184K in Q2 2015. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

EARNEST Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
EARNEST Partners sold 4,400 Acadia Pharmaceuticals shares in Q4 2018, an estimated $91K.
EARNEST Partners first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 17 quarters.
EARNEST Partners's Acadia Pharmaceuticals position peaked at $184K in Q2 2015.
186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on EARNEST Partners's 13F filing for Q4 2018, filed 14 Feb 2019.